Search

Your search keyword '"Tham, Wai-Hong"' showing total 316 results

Search Constraints

Start Over You searched for: Author "Tham, Wai-Hong" Remove constraint Author: "Tham, Wai-Hong"
316 results on '"Tham, Wai-Hong"'

Search Results

1. Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

2. Serological Markers of Exposure to Plasmodium falciparum and Plasmodium vivax Infection in Southwestern Ethiopia.

3. Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants

5. Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein

7. Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatment

8. Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2

9. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

10. Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesi

13. Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages

14. Plasmodium vivax binds host CD98hc (SLC3A2) to enter immature red blood cells

15. Activity Refinement of Aryl Amino Acetamides that Target the P. Falciparum Star-Related Lipid Transfer 1 Protein

16. Aryl amino acetamides prevent the development ofPlasmodium falciparumrings via inhibition of the lipid transfer protein PfSTART1

18. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

19. Development and validation of serological markers for detecting recent Plasmodium vivax infection

21. Evolutionary history of human Plasmodium vivax revealed by genome-wide analyses of related ape parasites

22. Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax

23. Structure of Plasmodium falciparum Rh5–CyRPA–Ripr invasion complex

29. Complement Receptor 1 availability on red blood cell surface modulates Plasmodium vivax invasion of human reticulocytes

30. Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2

31. Nanobodies against Pfs230 block Plasmodium falciparum transmission

32. Longitudinal IgG antibody responses to Plasmodium vivax blood-stage antigens during and after acute vivax malaria in individuals living in the Brazilian Amazon

33. Parallel use of pluripotent human stem cell lung and heart models provide new insights for treatment of SARS-CoV-2

34. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2

35. Altered affinity to ACE2 and reduced Fc functional antibodies to SARS-CoV-2 RBD variants

37. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax

39. Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma

40. Additional file 1 of Naturally acquired antibody kinetics against Plasmodium vivax antigens in people from a low malaria transmission region in western Thailand

41. Additional file 2 of Naturally acquired antibody kinetics against Plasmodium vivax antigens in people from a low malaria transmission region in western Thailand

42. Additional file 1 of Comparison of total immunoglobulin G antibody responses to different protein fragments of Plasmodium vivax Reticulocyte binding protein 2b

45. HeterologousSARS‐CoV‐2IgAneutralising antibody responses in convalescent plasma

47. Plasmodium vivax malaria serological exposure markers: assessing the degree and implications of cross-reactivity with P. knowlesi

49. Naturally acquired antibody kinetics against Plasmodium vivax antigens in people from a low malaria transmission region in western Thailand

Catalog

Books, media, physical & digital resources